The CDMO Samsung Biologics has announced that it has received the EcoVadis’ Platinum Sustainability Rating, the highest level of recognition for corporate sustainability performance.
The Platinum rating places Samsung Biologics in the top one per cent of companies evaluated globally by EcoVadis.
EcoVadis is a leading sustainability assessment platform that measures corporate social responsibility performance across four key areas: Environment, Labour & Human Rights, Ethics and Sustainable Procurement.
The EcoVadis rating is widely referenced by multinational organisations, including global pharmaceutical companies, as a key benchmark for supply chain sustainability and partnership evaluation.
EcoVadis recognised Samsung Biologics for the continued strengthening of its sustainability management systems and execution, reflecting progress across these assessment categories throughout its operations and supply chain.
The award builds on the company's Gold Sustainability Rating, received back in 2024.
"This recognition reflects the steady progress we have made in advancing sustainability practices across our operations and supply chain," said John Rim, President and CEO of Samsung Biologics.
"As ESG expectations continue to evolve globally, we remain focused on our commitment to responsible business practices that support long-term partnerships and contribute to a more sustainable healthcare ecosystem."
Samsung Biologics has continued to enhance its sustainability initiatives in recent years, including expanding the use of renewable energy across operations and reinforcing ethical and compliance frameworks.
The company received an ‘A’ rating in Water Security from the Carbon Disclosure Project (CDP) in December 2025.
As a champion of the Sustainable Markets Initiative Health Systems Task Force, Samsung Biologics also continues to engage global suppliers in decarbonisation efforts and the development of more resilient value chains.